Literature DB >> 28236156

Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review.

Kashif Jafri1, Hengameh Zahed2, Katherine D Wysham3, Sarah Patterson4, Amber L Nolan5, Matthew D Bucknor6, R Krishna Chaganti4.   

Abstract

Weakness, seizures, and encephalopathy have a broad differential diagnosis in patients with systemic lupus erythematosus (SLE). We present a case of a 26-year-old female with a recent diagnosis of SLE who experienced a clinical deterioration with quadriparesis, seizures, and encephalopathy. Her quadriparesis was found to be secondary to biopsy-proven hydroxychloroquine-induced myopathy with concomitant inflammatory myopathy. Her seizures and encephalopathy were suspected to be multifactorial in the setting of sepsis and critical illness with possible contributions from neuropsychiatric manifestations of SLE and macrophage activation syndrome. She experienced a dramatic clinical recovery with discontinuation of hydroxychloroquine, treatment of lupus disease activity with mycophenolate mofetil and prednisone, and antibiotic treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. This case-based review provides a systematic approach to quadriparesis, seizures, and encephalopathy in patients with SLE and an evidence-based discussion of antimalarial myopathy, which is of critical importance given the widespread use of antimalarial medications for rheumatologic diseases.

Entities:  

Keywords:  Adverse medication effect; Myopathy; Seizures; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 28236156     DOI: 10.1007/s10067-017-3579-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  29 in total

Review 1.  Drug-related myopathies of which the clinician should be aware.

Authors:  Ritu Valiyil; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.

Authors:  G K Bertsias; J P A Ioannidis; M Aringer; E Bollen; S Bombardieri; I N Bruce; R Cervera; M Dalakas; A Doria; J G Hanly; T W J Huizinga; D Isenberg; C Kallenberg; J C Piette; M Schneider; N Scolding; J Smolen; A Stara; I Tassiulas; M Tektonidou; A Tincani; M A van Buchem; R van Vollenhoven; M Ward; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2010-08-19       Impact factor: 19.103

3.  Inhibition of lysosomal function in red and white skeletal muscles by chloroquine.

Authors:  W T Stauber; A M Hedge; J J Trout; B A Schottelius
Journal:  Exp Neurol       Date:  1981-02       Impact factor: 5.330

4.  Musculoskeletal involvement in systemic lupus erythematosus.

Authors:  A Zoma
Journal:  Lupus       Date:  2004       Impact factor: 2.911

5.  Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature.

Authors:  J A Avina-Zubieta; E S Johnson; M E Suarez-Almazor; A S Russell
Journal:  Br J Rheumatol       Date:  1995-02

Review 6.  Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.

Authors:  Jessica E Nord; Prediman K Shah; Renee Z Rinaldi; Michael H Weisman
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

Review 7.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.

Authors:  G Ruiz-Irastorza; M Ramos-Casals; P Brito-Zeron; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 8.  The diagnosis and clinical management of the neuropsychiatric manifestations of lupus.

Authors:  M Govoni; A Bortoluzzi; M Padovan; E Silvagni; M Borrelli; F Donelli; S Ceruti; F Trotta
Journal:  J Autoimmun       Date:  2016-07-12       Impact factor: 7.094

9.  Neuropsychiatric systemic lupus erythematosus.

Authors:  Alexandra Popescu; Amy H Kao
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

10.  Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment.

Authors:  Anu Gupta; Yashdeep Gupta
Journal:  Indian J Endocrinol Metab       Date:  2013-09
View more
  2 in total

1.  Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.

Authors:  Lavanya Mittal; Lingqiao Zhang; Rui Feng; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2017-10-06       Impact factor: 11.527

Review 2.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.

Authors:  Romain Muller
Journal:  Rheumatol Int       Date:  2021-04-24       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.